-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PmX4qVimE/oV1CGhYxVscmVs9+LVGvfiw+K6BXmSQYGC1NiMxuNQbcIXF1aTuF4q OE3pBPhYY24veTZkKyc/+g== 0000814133-03-000047.txt : 20030214 0000814133-03-000047.hdr.sgml : 20030214 20030214150501 ACCESSION NUMBER: 0000814133-03-000047 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-53269 FILM NUMBER: 03566839 BUSINESS ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 9198621000 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: WASATCH ADVISORS INC CENTRAL INDEX KEY: 0000814133 IRS NUMBER: 870319391 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 150 SOCIAL HALL AVENUE STREET 2: SUITE 400 CITY: SALT LAKE CITY STATE: UT ZIP: 84111 BUSINESS PHONE: 8015330777 MAIL ADDRESS: STREET 1: 150 SOCIAL HALL AVENUE STREET 2: SUITE 400 CITY: SALT LAKE CITY STATE: UT ZIP: 84111 SC 13G/A 1 slxp203.txt SCHEDULE 13G Amendment No. 1 Name of Issuer: Salix Pharmaceuticals, Ltd. Title of Class of Securities: Common Stock CUSIP Number: 795435106 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 863,430 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 863,430 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 863,430 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 4.0% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Salix Pharmaceuticals, Ltd. Item l(b): Address of Issuer: 8540 Colonnade Center Drive, Suite 501, Raleigh, NC 27615 Item 2(a): Name of Person Filing: Wasatch Advisors, Inc. Item 2(b): Address: 150 Social Hall Avenue, Salt Lake City, UT 84111 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 03232P405 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 863,430 Item 4(b): Percent of Class Owned: 4.0% Item 4(c)(i): Sole Voting Power: 863,430 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 863,430 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [X] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2002. Date: 02/14/03 Signature: /s/Jeff S. Cardon Name/Title: Jeff S. Cardon/President -----END PRIVACY-ENHANCED MESSAGE-----